Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Key Stats

• Today's Range: $1.57 to $1.66
• 50-Day Range: $1.35 to $1.66
• 52-Week Range: $0.89 to $3.10
• Volume: 690,192 shs
• Average Volume: 835,539 shs
• Market Capitalization: $132.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Protalix BioTherapeutics Stock Analysis - MarketRank™

Protalix BioTherapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 420th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Protalix BioTherapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3,000.00%

Earnings Growth

Earnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protalix BioTherapeutics is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protalix BioTherapeutics is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protalix BioTherapeutics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.26% of the float of Protalix BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protalix BioTherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protalix BioTherapeutics has recently increased by 9.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protalix BioTherapeutics does not currently pay a dividend.

Dividend Growth

Protalix BioTherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.26% of the float of Protalix BioTherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protalix BioTherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Protalix BioTherapeutics has recently increased by 9.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.26

News Sentiment

Protalix BioTherapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Protalix BioTherapeutics this week, compared to 1 article on an average week.

Search Interest

Only 8 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Protalix BioTherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $206,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.50% of the stock of Protalix BioTherapeutics is held by insiders.

Percentage Held by Institutions

Only 16.53% of the stock of Protalix BioTherapeutics is held by institutions.

PLX Stock Analysis - Frequently Asked Questions

How have PLX shares performed this year?

Protalix BioTherapeutics' stock was trading at $1.88 at the beginning of the year. Since then, PLX shares have decreased by 11.7% and is now trading at $1.66.

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSE:PLX) issued its earnings results on Friday, May, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 30.89% and a negative net margin of 21.03%.

When did Protalix BioTherapeutics' stock split?

Protalix BioTherapeutics shares reverse split on the morning of Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Protalix BioTherapeutics' major shareholders?

Top institutional investors of Protalix BioTherapeutics include Geode Capital Management LLC (1.04%), Connor Clark & Lunn Investment Management Ltd. (0.62%), Evergreen Capital Management LLC (0.22%) and Diametric Capital LP (0.18%). Insiders that own company stock include Aharon Schwartz and Dror Bashan.
View institutional ownership trends.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protalix BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:PLX
• CIK: 1006281
• Web: www.protalix.com
• Phone: 201-696-9345
• Fax: 972-4988-9489
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Protalix BioTherapeutics: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +803.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 166.00
• P/E Growth: N/A
• Net Income: $8.31 million
• Net Margins: -21.03%
• Pretax Margin: -21.00%
• Return on Equity: -30.89%
• Return on Assets: -11.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.98
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $61.95 million
• Price / Sales: 2.14
• Cash Flow: $0.09 per share
• Price / Cash Flow: 17.80
• Book Value: $0.47 per share
• Price / Book: 3.53

Miscellaneous

• Outstanding Shares: 79,732,000
• Free Float: 68,995,000
• Market Cap: $132.36 million
• Optionable: Optionable
• Beta: -0.21